Protocol

MELBMS: A Phase 2 Study of Ipilimumab in Children and adolescents (12 to < 18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma

Diseases

Solid Tumor : Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma

Description

This is a non-randomized, multicenter, open label Phase 2 study in adolescent subjects (12 to <18 years of age) with previously treated or untreated unresectable Stage III or Stage IV malignant melanoma. This study will enroll approximately 30 patients.


Objectives


Eligibility Criteria among other include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE  (1-866-278-5833).


Contact

Alberto Pappo, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.